Gabapentin Capsule
Product Images NDC 50090-7420

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-7420). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Equation (Equation)

A mathematical formula for calculating creatinine clearance (CLCr), based on age, weight, and serum creatinine levels, with an adjustment factor for female patients. This formula is often used in pharmacokinetics relevant to drug dosing.*

FDA Label Image

Fig 1 (Fig 1)

A line graph depicting weekly mean pain scores over eight weeks comparing placebo and gabapentin 3600 mg/day. The x-axis shows weeks from baseline to week 8, and the y-axis presents mean pain scores on a scale from 0 to 10. The graph indicates two phases: a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Fig 2 (Fig 2)

A line graph showing weekly mean pain scores over a 7-week period in a study population. The chart compares placebo with gabapentin at 1800 mg/day and 2400 mg/day doses. The y-axis represents mean pain score and the x-axis represents weeks from baseline. Data is divided into 3-week dose titration and 4-week fixed dose periods.*

FDA Label Image

Fig 3 (Fig 3)

A bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing data from two studies comparing placebo (PBO) and gabapentin (GBP) at various doses. Study 1 shows 12% response for placebo and 29% for gabapentin 3600 mg. Study 2 shows 14% for placebo, 32% for gabapentin 1800 mg, and 34% for gabapentin 2400 mg. Statistical significance markers indicate p values below 0.01 and 0.001.*

FDA Label Image

Fig 4 (Fig 4)

A bar chart showing responder rates in patients receiving gabapentin compared to placebo by daily dose (600 mg, 1200 mg, and 1800 mg) across three studies (Study a, Study b, Study c). The y-axis represents the percentage difference in responder rate, and the chart illustrates variations for each dose and study in patients aged 12 years and older with partial seizures.*

FDA Label Image

Structure (Struct)

Chemical structure of gabapentin, illustrating a cyclohexane ring connected to amino (CH2NH2) and carboxyl (CH2CO2H) functional groups.*

FDA Label Image

Label Image (Lbl500907420)

Label for GABAPENTIN 300 mg oral capsules by A-S Medication Solutions. The label includes storage instructions to keep capsules at 77 degrees Fahrenheit, states a package quantity of 100 capsules, and displays the product NDC 50090-7420. The label also notes each capsule contains 300 mg of gabapentin, USP.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.